NCT04516278 - A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders | Biotech Hunter

Enrollment

195

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

February 10, 2021

Study Completion Date

February 10, 2021

Conditions

Age-related Macular DegenerationNeovascular Age-related Macular DegenerationWet Macular DegenerationBRVO - Branch Retinal Vein OcclusionDiabetic Macular Edema

Interventions

BIOLOGICAL

bevacizumab

1.25 mg, intravitreal injection

Trial Locations (20)

17201

Clinical Site, Chambersburg

21740

Clinical Site, Hagerstown

33761

Clinical Site, Clearwater

33880

Clinical Site, Winter Haven

38138

Clinical Site, Germantown

57701

Clinical Site, Rapid City

60452

Clinical Site, Oak Forest

62704

Clinical Site, Springfield

76012

Clinical Site, Arlington

76087

Clinical Site, Willow Park

78251

Clinical Site, San Antonio

78503

Clinical Site, McAllen

79606

Clinical Site, Abilene

85710

Clinical Site, Tucson

87109

Clinical Site, Albuquerque

90211

Clinical Site, Beverly Hills

90807

Clinical Site, Long Beach

91203

Clinical Site, Glendale

92064

Clinical Site, Poway

92260

Clinical Site, Palm Desert